When #prostatecancer just ain’t cancer. 👀 👇 www.sciencedirect.com/science/arti... Re: Rajal B. Shah et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: doi.org/10.1016/j.eu... @dr-coops.bsky.social

Good concise article on the status of Active Surveillance for Prostate Cancer. As treatment/surveillance becomes more precise, Screening becomes more palatable for Primary Care. via @dr-coops.bsky.social #MensHealth cuaj.ca/index.php/jo...

Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm acsjournals.onlinelibrary.wiley.com/doi/epdf/10....

Initial active surveillance and watchful waiting significantly increased for intermediate–risk prostate cancer between 2010 and 2020. https://ja.ma/4042hPZ

It is with great sadness that we mourn our cherished friend and colleague Felix Feng, MD. Felix was a distinguished physician-scientist and beloved at @ucsfhealth.bsky.social. His vision, dedication, and commitment inspired colleagues, peers everywhere, and patients. cancer.ucsf.edu/in-memoriam-...

Spotted outside the UMich reception at #SUO24 — thx to Dallas for customizing your neon for the Urology meeting 🤣

Brian Thompson’s assassination is a horrifying and tragic. But maybe something good will come of this renewed conversation about an industry whose _entire_ business model has been based for decades on profiting at the expense of patients and providers. apple.news/ASy_o_WGXRI6...

Great updates from Patrick Hensley and Mark Tyson on the huge and growing array of options for non-muscle-invasive #bladdercancer #SUO24

How often is AS/WW used in int risk prostate cancer? Leapman et al @yalecancer.bsky.social report in JAMA that AS/WW use increased from 5 - 12.3% from 2010-20, most in GG1 dz. Treat high-risk disease early, but offer AS/WW for low + some int risk cancers. jamanetwork.com/journals/jam...

It was great to have the chance to chat with @gabecanales.bsky.social last week about low-risk #prostatecancer and active surveillance x.com/gabecanales/... @bluecure.bsky.social

Happy 76th birthday to 2009 Nobel Prize recipient Elizabeth Blackburn, whose 1984 discovery of telomerase not only demonstrated that cells can use RNA to construct DNA, but has spawned an entire field of biological study. tinyurl.com/47zp8azb #WomenInSTEM #HistSci #BioSky 🧪

Good morning! Recommending a number of our early adopters & growing list of #OncSky heavy hitters to follow: @sueyom.bsky.social @andreigoga.bsky.social @dr-coops.bsky.social @drkomanduri.bsky.social @atulbutte.bsky.social @hoperugo.bsky.social @hemedoc.bsky.social and more: bsky.app/profile/did:...

jamanetwork.com/journals/jam... #Overtreatment of #prostatecancer persists, especially using #radiotherapy. This continues to be the biggest barrier to equitable #populationscreening for #earlydetection. We must stop doing it. #activesurveillance @uroweb.bsky.social

Here hoping this is a false prediction! apple.news/AIY9nd6fESyi...

ICYMI: *30* year outcomes from SPCG-4 dx.doi.org/10.1056/NEJM... RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

Active surveillance for intermediate-risk prostate cancer rose from 5% in 2010 to 12.3% in 2020. Most common in GG1 cases (53.8% by 2020). PSA and GG remain key factors. #ProstateCancer #ActiveSurveillance #Oncology #CancerResearch @oncoalert.bsky.social

Ok, maybe AI is even coming for surgery in our lifetime…! scitechdaily.com/robot-that-w...

This is not the first time. It’s not even the first time this decade! prospect.org/culture/book...

To echo @dr-coops.bsky.social i thought we could thread some of the most interesting #BladderCancer papers over the last few months ... that might have missed discussion @alisonbirtle.bsky.social @bladdercancer.bsky.social .....

Nice article about our new #UroSoMe home… I’m optimistic! But can you believe there are only 20 people running this show #bluesky?? www.nytimes.com/2024/11/17/t...

What’s your single favorite #prostatecancer paper of the year so far? I’ll lead with PI-CAI: big leap forward for prostate MRI through a highly collaborative AI effort. And the best part is it’s all free and *open-source*! ⭐️ www.thelancet.com/journals/lan...

Ok Not really sure what I’m doing but this #ProstateCancer starter pack has been created It is meant to be INclusive so please let me know if you know anyone who wants so “join” @asharpmedonc.bsky.social @nimasharifimd.bsky.social @alison-tree.bsky.social @profiand.bsky.social go.bsky.app/ANw3D3j

Great day spent on strategic planning with AUA to improve Urology clinical trial participation at both patient and provider level. Stay tuned! @dr-coops.bsky.social

GU starter pack… started! Let me know if you want to be added. go.bsky.app/DtoXvaD #Genitourinary #Oncology #GUonc #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Medtwitter

It was a pleasure to join Dr Geo Espinoza for a great dialog re: #prostatecancer diagnostics and related topics Modern and Best Methods to Diagnose Prostate Cancer youtu.be/ZLpcd-0oM0E?...

I'm thrilled to be able to share this report from the symposium CAncer or Not Cancer?: Evaluating and Reconsidering GG1 #prostatecancer (CANCER-GG1?), out recently in JNCI: “When is prostate cancer really cancer?” doi.org/10.1093/jnci...